Search

It is also refrigerated for 3 times more good bacteria compared with the leading extra strength probiotic and is the no. 1 pharmacist-recommended refrigerated probiotic. SEE OUR AD ON PAGE 47 Plan B One-Step From Duramed Pharmaceuticals, Inc. Plan B One-Step is the no. 1 recommended emergency contraception brand by obstetrician-gynecologists and is available in all 50 states in the US with no identification or prescription required. FOR MORE INFORMATION: florajen.com SEE OUR AD ON PAGE 17 RepHresh Pro-B From Church & Dwight, Co, Inc RepHresh Pro-B is a daily oral probiotic supplement uniquely developed for vaginal health. [Extracted from the article]

The article focuses on mifepristone and pasireotide, two investigational drugs that have the potential to treat Cushing's syndrome, according to endocrinology experts.

Choices in emergency contraception are currently fairly limited, but new options are currently under investigation. Teenage pregnancy is an important public and social health issue in England and Wales. Emergency contraception remains a highly effective method of reducing teenage pregnancy rates in the event of contraceptive mishaps and unprotected sexual intercourse. The combined oestrogen-progestogen method of hormonal emergency contraception was licensed in Great Britain in 1984. Mifepristone has been studied to establish the optimal dose for emergency contraception.

The article presents a discussion of a study on the use of mifepristone to treat central serous chorioretinopathy (CSC), adapted from a presentation by Roger Goldberg at the 2018 meeting of the American Society of Retina Specialists (ASRS) in Vancover, British Columbia. The study showed the drug's efficacy to improve sub-retinal fluid and best-corrected visual acuity (BCVA) in CSC patients. It also identified the risk factors for CSC, including systemic hypertension and pregnancy.

The article reports on the increasing interest of women in areas infiltrated by the Zika virus in obtaining anti-ulcer and drugs mifepristone and misoprostol, according to the publication "New England Journal of Medicine. A list is presented of countries with growing online requests for the medications through the Women on Web resource.

The article discusses the issue of allowing nurses to supply the abortion pill mifepristone in Great Britain. One asserts that nurses should prescribe the abortion pill early on in pregnancy. Another comments that the over usage of abortion pills could have dangerous side effects on the users. Another discusses that the British Pregnancy Advisory Service should invest more money to promote and highlight the importance of contraception and better sex education.

Focuses on the attempt of United States President Bill Clinton's administration to propose and finalize major health and environmental rules. Reaction of Republican members of the U.S. Congress; Approval of the abortion pill RU-486 by the U.S. Food and Drug Administration; Organic food production standards; Proposed rule on diesel exhaust.

Presents information on the resolutions adopted by the National Organization for Women during its 2000 National Conference in the United States. Economic human rights; Availability of the mifepristone drug for women; Protection of supporters of Vermont civil unions; Funds for the Violence Against Women Act of 1994.

The article discusses a phase 3 study on the safety and effectiveness of mifepristone for treatment of patients with Cushing's syndrome.

The article reports on the study on mifepristone conducted by Wolfgang S. L. Strauss of the University of Ulm in Germany and Hans-Wolfgang Schramm of University of Graz in Austria. It states that mifepristone, also known as RU 486, can already be used in the advancement of diagnostic imaging and treatment of cancer. It mentions that mifepristone's capacity to advance cancer treatment was made through the replacement of its dimethylaminophenyl with several linker groups.

The law on abortion should be changed to allow nurses and mdiwives to perform early surgical abortions and prescribe mifepristone (RU486), the RCN has told MPs. [ABSTRACT FROM AUTHOR]

Traces the history of the development of the drug RU-486, a hormone which is better known as the abortion pill. Chemical name; CAS Registry number; Other names; Year introduced; Company which introduced the drug; Sales volume; Actions of the drug; Negative effects; Companies which produce the drug.

Reports that the U.S. Food and Drug Administration will revise the warning label of mifepristone, an abortion pill also known as RU-486. Information on mifepristone; Reason behind the revision.

Focuses on the vigilance of feminist groups in the United States against anti-abortion groups efforts to limit the use and prescription of abortion drug Mifepristone. Approval granted by the United States Food and Drug Administration for the distribution of the drug; Importance of the drug to abortion activists.

Reports the approval of RU-486, an abortifacient distributed by Danco Laboratories as Mifeprex by the United States Food & Drug Administration. Composition of the synthetic steroid; Account of the news conference conducted by the drug supporters; Details on the research and development on fertility control.

Presents information on the resolution passed by the National Organization for Women addressing the United States (U.S.) government to approve the use of the drug mifepristone. Use of the drug as an alternative to surgical abortion; Views of the U.S. Food and Drug Administration regarding the drug; Campaign of reproductive rights supporters and feminists for the drug's approval.

Presents several news about pharmaceuticals. Findings of a study in one of four Massachusetts pharmacies regarding its closure; Report from the Quarterly Pharmaceutical Pricing about the health care expenses, prescription drug costs; Issue on RU-486, an abortifacient drug regarding its manufacturing.

Highlights a report by an Institute of Medicine panel on research on the Roussel-Uclaf antiprogesterin mifepristone or RU-486. Blockage of progesterone, a steroid hormone necessary for establishing and maintaining pregnancy; Use in inducing early abortions; Assessment of efficacy, toxicity and long-term safety; Other recommendations.

Deals with the Hoechst's transfer of patents and inventory of Roussel Uclaf (RU)-486 abortifacient to Edouard Sakiz company. Reason for the transfer; What prompted the decision; Donation of Hoechst of US patent rights and technology; Other information.

Reveals that a search is on to find United States companies willing to produce the abortifacient RU-486. Hoechst subsidiary Roussel Uclaf's donation of the patent rights and technology for RU-486 to the research organization Population Council.